Founded December 2016 (incubated)
Stage Business development
Investors The Trendlines Group; Technion-Israel Institute of Technology
CEO Hezkiah Tsoory
liberDi is the world’s first all-in-one portable dialysis device that provides safe self-care anywhere (under remote medical supervision) and replaces the need for full-service, in-clinic care!
For many dialysis patients, liberDi replaces the need for the traditional full-service, in-clinic care. Patients who use the liberDi system are “liberated” to live their lives and enjoy safe treatment anywhere.
The liberDi Advantages
The market seeks an effective, easy-to-use dialysis solution for improved treatment benefits and reduced health care costs.
See the liberDi animation.
Hezkiah Tsoory, Founder & CEO: Extensive experience in international business, operations, R&D; former VP Business Development, Nanocell; COO, D Medical Industries (TASE, Nasdaq: DMED), COO, MCS (TASE: MDCL); VP Operations, Mentorwave; VP Manufacturing, Power Paper
Over 20 years’ experience as a specialist in nephrology and hypertension; Head, Department of Nephrology and Hypertension, Carmel Medical Center, Haifa, Israel; VP, Israeli Society of Nephrology and Hypertension
Head of Dialysis Unit, Carmel Medical Center, Haifa, Israel; specialist in nephrology and internal medicine; 20 years’ experience in nephrology; organizer, Israel PD Academy
Previously, Head of the Institute of Nephrology, Rabin Medical Center (Beilinson & Hasharon hospitals), Petah Tikva, Israel. Extensive clinical and research experience in the field of nephrology in general and peritoneal dialysis in particular
Head, Peritoneal Dialysis Unit, Imperial College Kidney and Transplant Centre, Hammersmith Hospital, London, UK; co-organizer, UK PD Academy; extensive research and education related to outcomes of older patients on dialysis; Chair, Guidelines Committee, International Society of Peritoneal Dialysis
One-tenth of the world’s population is affected by kidney disease. The rise in obesity, diabetes, and stress-related illnesses are leading to a 5% to 7% increase in the number of patients every year. Kidney disease is one of the most expensive chronic diseases to treat, costing $114 billion in the United States alone.
Hemodialysis (HD), the most common treatment method (89%), takes place at clinics, where it is supervised by medical personnel. Patients commonly undergo three dialysis sessions a week.
Clinics are obliged to provide full services to a growing number of patients, struggling to do so under mounting costs, as government reimbursements (a major revenue source) decline and don’t cover the costs, let alone allow for making a profit.
This economic challenge can be solved with self-care at home, using peritoneal dialysis (PD), which costs considerably less. Today, only 11% of patients globally use PD because doctors who recommend it as a first modality are faced with
patients’ lack of confidence. Current PD options require a complex procedure that many patients can’t follow, which may reduce treatment efficacy and may increase the risk of infection.